Goldman Sachs lowers Corteva stock price target to $20 post-spinoff

After Corteva spun off seed business Vylor—which represented about two-thirds of the former company’s sales and EBITDA—Goldman Sachs cut its price target to $20 from $96 but maintained Buy, implying about 38% upside from Corteva’s $14.45 share price. The stock gained 15% over the past week; Goldman projects $600 million in annual free cash flow in 2027–29 and values the company at 10.5x EV/EBITDA, while accounting for $1.75 billion in predecessor liabilities. Other firms also reset targets following the spin-off, with ratings ranging from Outperform to Overweight; BMO cited crop-protection headwinds.

Analysis

The key issue is price discovery after a major change in what CTVA owns—not a sudden collapse in the value of the same business. Pre-spin analyst targets are no longer comparable: the retained company is now more concentrated in crop protection, while Vylor holds the seed business. Post-spin trading and analyst estimates may remain distorted by mandate-driven reallocations and incomplete standalone financial baselines; low apparent multiples are not persuasive until EBITDA, share count, debt and liabilities are consistently rebased.

Over 1–3 months, watch for standalone results and guidance that establish crop-protection earnings power and clarify allocation of PFAS and pension obligations. The seed/chemistry separation could weaken bundled selling or cross-selling, potentially helping rival suppliers if customers gain leverage—but that is a hypothesis to test against retention, pricing and order data. Over 6–18 months, seasonal working-capital swings and crop-protection pricing will matter more than the headline post-spin valuation. Goldman’s FCF projection and valuation multiple are estimates, not verified outcomes; the stated seasonal net-debt profile also makes annual cash conversion important.

Contrarian read: the sharp target resets are mostly a scope change, not evidence of equivalent fundamental downgrades. But the cited upside is not independently established without a reconciled post-spin model. No forced trade yet; the cleaner opportunity is likely after liquidity and financial baselines normalize.

Key Decisions for Investors

• Do not anchor on pre-spin targets or treat the post-spin P/E and EV/EBITDA as independently validated. Rebuild CTVA on standalone diluted shares, EBITDA, cash/debt and liability allocations before sizing a position.
• Keep CTVA on a catalyst watchlist; consider a measured long only after the first standalone guidance/results confirm crop-protection earnings and cash conversion. The near-term thesis is falsified by a material guidance cut, weaker-than-expected pricing/order trends, or a deterioration in net debt beyond seasonal timing.
• Track Vylor’s customer retention and any evidence of reduced seed/chemistry bundling alongside competitor pricing. If separation weakens CTVA’s selling proposition, reassess the long thesis; do not infer that effect from the spin alone.
• Verify the post-spin PFAS and pension liability allocation, seasonal working-capital needs, and the basis for the projected $600 million annual FCF. Until these are reconciled, treat the analyst-derived upside as an alert—not a price target or standalone trade signal.